2026-05-31T21:03:35Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/339352026-02-03T11:15:24Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc Órpez-Zafra, Teresa author Pavía-Molina, José author Pinto-Medel, Maria Jesús author Hurtado-Guerrero, Isaac author Rodríguez-Bada, José Luis author Martín-Montañez, Elisa author Fernández Fernández, Óscar author Leyva-Fernández, Laura author Oliver-Martos, Begoña author 2015 Aim: The soluble isoform of the IFN-β receptor (sIFNAR2) can bind IFN-β and modulate its activity, although its role in autoimmune diseases remains unknown. Methods: A recombinant human sIFNAR2 protein was cloned, expressed and purified after which we developed and validated an ELISA for its quantification in human serum. Serum sIFNAR2 were assessed in multiple sclerosis (MS) patients and healthy controls. Results: The ELISA has a dynamic range of 3.9-250 ng/ml and a detection limit of 2.44 ng/ml. Serum sIFNAR2 were significantly lower in untreated-MS patients than in healthy controls. Conclusion: The ELISA is suitable for quantification of sIFNAR2 in serum and should facilitate the study of sIFNAR2 in neuroimmunological diseases such as MS. Órpez-Zafra T, Pavía J, Pinto-Medel MJ, Hurtado-Guerrero I, Rodriguez-Bada JL, Martín Montañez E, Fernández Ó, Leyva L, Oliver-Martos B. Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosis. Bioanalysis. 2015;7(22):2869-80. doi: 10.4155/bio.15.208. Epub 2015 Nov 16. PMID: 26571364. https://hdl.handle.net/10630/33935 10.4155/bio.15.208 Esclerosis múltiple Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosis